TORONTO, July 4, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) (the "Company") is pleased to announce that it has completed the previously-announced acquisition of 51% of issued and outstanding shares of Meck Medical GmbH ("MECK"). Klingenberg Germany-based MECK is a developer of innovative healthcare software solutions assembled into a cloud-based platform that provides facility management services, document management, prescription management, wound management and social networking services to the long term care, nursing home and extended care industries in Germany.
In connection with the acquisition, the Company has agreed to provide MECK a loan to fund its operations of up to 100,000 Euros per month to a maximum of 2.4 million Euros in the aggregate. MECK is required to have a reserve pool of not less than 50,000 Euros at all times. The loan will bear interest at 5.75% per annum and is repayable based on future MECK profits with maturity in 5 years from the date of the first advance. In connection with the acquisition, MECK has agreed to pay a co-founder a total of 1,000,000 Euros over 8 quarters starting in August 2014 to acquire certain intellectual property.
In order to finance the cash portion of the purchase price for the MECK acquisition and related transaction costs, the Company arranged for an arm's length, unsecured demand loan in the principal amount of 1.2 million Euros, with interest payable at the Bank of England prime rate plus 3% per annum.
Over the past few months, management of the Company has been in discussions to secure sufficient financing to support the ongoing cash requirements of its operations and complete acquisitions, including the previously-announced QLINE Solutions Inc. transaction which has not yet closed. Although the Company has been able to secure a portion of the required funding, management is continuing its efforts to secure additional funding for the Company's short and long-term obligations. The financing alternatives include debt and/or equity financings, asset sales and rights offerings to existing shareholders. While the Company is striving to achieve its financing plans, there is no assurance that future funding will be available on favourable terms to the Company, or at all.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and the Company's actual results could differ materially from those anticipated. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the Company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information: Robert Kaul, Chief Executive Officer, Biosign Technologies, Phone: (416) 218-9800 ext. 201, Email: [email protected]